Company Overview - MaiBo Pharmaceutical Co., Ltd. (stock code 02181.HK) is a publicly listed company on the Hong Kong Stock Exchange, focusing on the research and production of new drugs and biosimilars for cancer and autoimmune diseases [2] - The company aims to deliver high-quality and affordable innovative biopharmaceuticals through an efficient R&D system and low-cost production capabilities [2] - MaiBo has developed a robust R&D and industrialization platform, mastering core technologies for large-scale antibody drug preparation, and has three antibody drugs successfully approved for market sale [2] Financial Performance - As of December 31, 2024, MaiBo achieved total revenue of 258 million yuan, representing a year-on-year growth of 196.27% [1] - The company reported a net profit attributable to shareholders of -128 million yuan, with a year-on-year increase of 38.89% [1] - The gross profit margin stood at 84.96%, while the debt-to-asset ratio was 91.25% [1] Market Performance - As of August 11, the stock price of MaiBo Pharmaceutical-B was 0.71 HKD per share, reflecting a 22.41% increase with a trading volume of 2.261 million shares and a turnover of 1.4792 million HKD [1] - Over the past month, the stock has seen a cumulative increase of 16%, and since the beginning of the year, it has surged by 107.14%, outperforming the Hang Seng Index by 23.92% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is -1.18 times, with a median of 4.48 times [1] - MaiBo's P/E ratio is -17.31 times, ranking 116th in the industry [1] - Comparatively, other companies in the sector have P/E ratios such as Jingxin Pharmaceutical (1.29 times), Kingsray Biotechnology (1.61 times), Dongrui Pharmaceutical (3.35 times), Hutchison China MediTech (5.61 times), and Jilin Changlong Pharmaceutical (5.89 times) [1]
迈博药业-B（02181.HK）8月11日收盘上涨22.41%，成交147.92万港元